 NEWARK, Calif., Oct. 11, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX Protagonist or the Company today announced that the U.S. Food and Drug Administration FDA has removed the full clinical hold on the Companys rusfertide clinical studies, announced on September 17, 2021. 